Skip to main content

Table 2 Patient characteristics. (2) Discontinuation/change group

From: A laboratory data-based evaluation of the efficacy and safety of generic pravastatin sodium for long-term use

  Concomitant drug-change Drug-change Dose-adjustment Discontinuation (short-term)
Patients (N) 37 329 98 278
Men/women (N) 24/13 150/179 44/54 103/175
Mean age (years) 66.7 66.8 68.1 70.9
Mean treatment duration (weeks) 144 ± 3.50 66.6 ± 3.53 143 ± 3.71 63.8 ± 4.00
  Age (years) Duration (weeks)
  Mean S.D. Mean S.D.
Long-term continued use 68.8 10.9 177 3.61
Discontinuation (long-term) 73.8 11.8 158 3.54
Concomitant drug-change 66.7 11.0 144 3.50
Drug-change 66.8 11.1 66.6 3.53
Dose-adjustment 68.1 11.2 143 3.71
Discontinuation (short-term) 70.9 12.5 63.8 4.00
  1. Standard deviation, S.D